Cliff Asness's ALLO Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 2.48 M shares of Allogene Therapeutics, Inc. (ALLO) worth $6.06 M, representing 0.00% of the portfolio. First purchased in 2020-Q3, this medium-term investment has been held for 15 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in ALLO, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 1.77 M shares. Largest reduction occurred in Q4 2025, reducing 424,307 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Allogene Therapeutics (ALLO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Allogene Therapeutics (ALLO) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +1.06 M | Add 73.85% | 2.48 M | $2.44 |
| Q4 2025 | -424,307 | Reduce 22.89% | 1.43 M | $1.37 |
| Q3 2025 | +1.77 M | Add 2199.01% | 1.85 M | $1.24 |
| Q2 2025 | +22,401 | Add 38.47% | 80,624 | $1.13 |
| Q1 2025 | +58,223 | New Buy | 58,223 | $1.46 |
| Q4 2024 | -33,589 | Sold Out | 0 | $0.00 |
| Q3 2024 | +6,302 | Add 23.10% | 33,589 | $2.80 |
| Q2 2024 | +27,287 | New Buy | 27,287 | $2.33 |
| Q2 2022 | -73,717 | Sold Out | 0 | $0.00 |
| Q1 2022 | +44,832 | Add 155.21% | 73,717 | $9.12 |
| Q4 2021 | +8,591 | Add 42.33% | 28,885 | $14.92 |
| Q3 2021 | -16,423 | Reduce 44.73% | 20,294 | $25.72 |
| Q2 2021 | +36,717 | New Buy | 36,717 | $26.09 |
| Q4 2020 | -8,576 | Sold Out | 0 | $0.00 |
| Q3 2020 | +8,576 | New Buy | 8,576 | $37.66 |
Cliff Asness's Allogene Therapeutics Investment FAQs
Cliff Asness first purchased Allogene Therapeutics, Inc. (ALLO) in Q3 2020, acquiring 8,576 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Allogene Therapeutics, Inc. (ALLO) for 15 quarters since Q3 2020.
Cliff Asness's largest addition to Allogene Therapeutics, Inc. (ALLO) was in Q3 2025, adding 1,853,554 shares worth $2.3 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 2,484,780 shares of Allogene Therapeutics, Inc. (ALLO), valued at approximately $6.06 M.
As of the Q1 2026 filing, Allogene Therapeutics, Inc. (ALLO) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Allogene Therapeutics, Inc. (ALLO) was 2,484,780 shares, as reported at the end of Q1 2026.